CN113559324B - Application of nano compound liquid in chondrocyte self-repair and regenerative medicine aesthetics - Google Patents
Application of nano compound liquid in chondrocyte self-repair and regenerative medicine aesthetics Download PDFInfo
- Publication number
- CN113559324B CN113559324B CN202110775346.9A CN202110775346A CN113559324B CN 113559324 B CN113559324 B CN 113559324B CN 202110775346 A CN202110775346 A CN 202110775346A CN 113559324 B CN113559324 B CN 113559324B
- Authority
- CN
- China
- Prior art keywords
- nano
- cartilage
- bone morphogenetic
- morphogenetic protein
- repair
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 30
- 239000007788 liquid Substances 0.000 title claims abstract description 26
- 239000003814 drug Substances 0.000 title abstract description 16
- 230000001172 regenerating effect Effects 0.000 title abstract description 4
- 210000001612 chondrocyte Anatomy 0.000 title description 15
- 239000004005 microsphere Substances 0.000 claims abstract description 34
- 239000002245 particle Substances 0.000 claims abstract description 32
- 210000000845 cartilage Anatomy 0.000 claims abstract description 31
- 230000008439 repair process Effects 0.000 claims abstract description 26
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 claims abstract description 24
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 claims abstract description 24
- 229940112869 bone morphogenetic protein Drugs 0.000 claims abstract description 24
- 239000002537 cosmetic Substances 0.000 claims abstract description 11
- 238000002360 preparation method Methods 0.000 claims abstract description 9
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims abstract description 7
- 239000007853 buffer solution Substances 0.000 claims abstract description 7
- 229920002674 hyaluronan Polymers 0.000 claims abstract description 7
- 229960003160 hyaluronic acid Drugs 0.000 claims abstract description 7
- 239000000945 filler Substances 0.000 claims abstract description 5
- 238000000034 method Methods 0.000 claims description 16
- 206010007710 Cartilage injury Diseases 0.000 claims description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 9
- 229920001661 Chitosan Polymers 0.000 claims description 9
- 239000000047 product Substances 0.000 claims description 8
- 239000006228 supernatant Substances 0.000 claims description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 6
- KBPLFHHGFOOTCA-UHFFFAOYSA-N caprylic alcohol Natural products CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 claims description 6
- 239000012154 double-distilled water Substances 0.000 claims description 6
- 239000012530 fluid Substances 0.000 claims description 6
- 238000005303 weighing Methods 0.000 claims description 6
- 230000015572 biosynthetic process Effects 0.000 claims description 5
- 230000001954 sterilising effect Effects 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 5
- 238000003786 synthesis reaction Methods 0.000 claims description 5
- 238000005406 washing Methods 0.000 claims description 5
- 239000002131 composite material Substances 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 239000011550 stock solution Substances 0.000 claims description 4
- 239000008346 aqueous phase Substances 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 3
- TVMXDCGIABBOFY-UHFFFAOYSA-N n-Octanol Natural products CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 claims description 3
- 239000002114 nanocomposite Substances 0.000 claims description 3
- 239000003761 preservation solution Substances 0.000 claims description 3
- 238000004659 sterilization and disinfection Methods 0.000 claims description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 2
- 229940098773 bovine serum albumin Drugs 0.000 claims description 2
- 239000004593 Epoxy Substances 0.000 claims 1
- 239000011449 brick Substances 0.000 claims 1
- 239000004067 bulking agent Substances 0.000 claims 1
- 238000005119 centrifugation Methods 0.000 claims 1
- 238000005516 engineering process Methods 0.000 abstract description 13
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 13
- 230000006698 induction Effects 0.000 abstract description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 5
- 230000006378 damage Effects 0.000 abstract description 4
- 210000003321 cartilage cell Anatomy 0.000 abstract description 3
- 230000003213 activating effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 30
- 210000001188 articular cartilage Anatomy 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 230000007547 defect Effects 0.000 description 12
- 238000002054 transplantation Methods 0.000 description 10
- 210000000988 bone and bone Anatomy 0.000 description 9
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 239000000017 hydrogel Substances 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 239000004475 Arginine Substances 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 description 5
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 description 5
- 238000012258 culturing Methods 0.000 description 5
- 230000004069 differentiation Effects 0.000 description 5
- 102000000503 Collagen Type II Human genes 0.000 description 4
- 108010041390 Collagen Type II Proteins 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 239000002105 nanoparticle Substances 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000008929 regeneration Effects 0.000 description 4
- 238000011069 regeneration method Methods 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- 208000013201 Stress fracture Diseases 0.000 description 3
- RGCKGOZRHPZPFP-UHFFFAOYSA-N alizarin Chemical compound C1=CC=C2C(=O)C3=C(O)C(O)=CC=C3C(=O)C2=C1 RGCKGOZRHPZPFP-UHFFFAOYSA-N 0.000 description 3
- 210000002744 extracellular matrix Anatomy 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000011164 ossification Effects 0.000 description 3
- 210000004409 osteocyte Anatomy 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 230000008733 trauma Effects 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 208000006735 Periostitis Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 238000005299 abrasion Methods 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000007664 blowing Methods 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000002316 cosmetic surgery Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000002055 immunohistochemical effect Effects 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 210000000629 knee joint Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 239000002121 nanofiber Substances 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 210000003460 periosteum Anatomy 0.000 description 2
- 108010011110 polyarginine Proteins 0.000 description 2
- 239000002861 polymer material Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000036487 Arthropathies Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 101000762366 Homo sapiens Bone morphogenetic protein 2 Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 101100025201 Mus musculus Msc gene Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000004550 Postoperative Pain Diseases 0.000 description 1
- 108010081750 Reticulin Proteins 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 241001447056 Uristes Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000001153 anti-wrinkle effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000009455 aseptic packaging Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 230000008355 cartilage degradation Effects 0.000 description 1
- 230000022159 cartilage development Effects 0.000 description 1
- 230000003848 cartilage regeneration Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000000968 fibrocartilage Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 210000003035 hyaline cartilage Anatomy 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000008407 joint function Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000001365 lymphatic vessel Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- 239000002923 metal particle Substances 0.000 description 1
- 238000002324 minimally invasive surgery Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000004218 nerve net Anatomy 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000002188 osteogenic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000007281 self degradation Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/227—Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/20—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y40/00—Manufacture or treatment of nanostructures
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/62—Encapsulated active agents, e.g. emulsified droplets
- A61L2300/622—Microcapsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/06—Materials or treatment for tissue regeneration for cartilage reconstruction, e.g. meniscus
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Dermatology (AREA)
- Nanotechnology (AREA)
- Molecular Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biophysics (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- General Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Manufacturing & Machinery (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Materials For Medical Uses (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention provides a nano compound liquid for cartilage repair, which comprises PBS buffer solution, hyaluronic acid and a nano microsphere particle compound, wherein the nano microsphere particle compound comprises microsphere particles, a filling agent and bone morphogenetic protein analogues. The invention further discloses a preparation method of the nano compound liquid for cartilage repair. The invention utilizes the bone morphogenetic protein analogue active peptide to prepare the nano microsphere particle compound with the slow release function and the corresponding nano compound liquid, the induction of cartilage cells is realized by utilizing the prepared compound liquid, and the compound liquid can be widely applied to the damage of joints and cartilage and the cosmetic repair by activating a human body self-healing system based on a liquid layering hydrodynamic soft stripping (water stripping) technology, has extremely high popularization value, and can be widely applied to the autologous repair of cartilage cells and the aesthetic of regenerative medicine.
Description
Technical Field
The invention relates to the field of biomedical engineering, in particular to a nano compound liquid for cartilage injury regeneration and application of the nano compound liquid in chondrocyte self-repair and regenerative medicine aesthetics.
Background
In recent years, articular cartilage injuries caused by trauma, inflammation, degeneration and the like are quite common in clinic, and are accompanied by obvious symptoms such as joint pain, joint deformity, even joint dysfunction and the like, so that the health condition and the life quality of the people are seriously affected.
Since articular cartilage is not innervated by blood vessels, lymphatic vessels, and nerves, it is difficult to restore its original structure and state once abrasion or trauma has occurred. Articular cartilage contains only a single cell type, chondrocytes. The growth of chondrocytes itself is restricted, and thus, articular cartilage is difficult to repair itself after it is damaged. The avascular microenvironment of cartilage results in restricted nutrient exchange or cartilage precursor cell circulation in the articular cartilage, impeding the healing process in the damaged area. Although surgical treatments such as stem cell stimulation, allograft and autograft may be helpful in some respects to restore cartilage function, these conventional treatments have limitations including cartilage degradation, poor integration with host tissues, secondary surgery, etc.
In addition, cartilage defects and damage can cause post-traumatic Osteoarthritis (OA), increasing the difficulty of healing cartilage damage. Therefore, repair of articular cartilage damage has been one of the major clinical problems. The cartilage repairing treatment method includes microfracture technology, tissue engineering technology, cartilage and periosteum transplantation technology and gene therapy technology. The microfracture technology is characterized in that bone marrow mesenchymal stem cells, growth factors and the like released by punching holes in a cartilage defect area are utilized to form a microscopic blood clot, the microscopic blood clot is differentiated into fibrocartilage tissues, and traditional treatment methods for promoting cartilage regeneration, such as microfracture, mosaic plasty, autologous chondrocyte transplantation, allogeneic bone/cartilage transplantation and the like, can relieve pain and improve joint functions, however, the generated new cartilage usually forms type I collagen, lacks the characteristics of hyaline cartilage of type II collagen, and has poor long-term clinical effect. The artificial joint replacement has the problems of prosthesis abrasion, corrosion, looseness and the like, and is limited in applicable population. Therefore, the existing repair methods aiming at the articular cartilage damage only temporarily relieve symptoms, but not cure the articular cartilage damage, and functional cartilage is not regenerated. In addition, osteochondral transplantation and autologous chondrocyte transplantation are also known. Osteochondral transplantation is a method in which cartilage conforming to the size of an injured site is removed from a secondary site in a knee joint and then implanted into a cartilage defect. Although surgery is successful and eliminates the risk of immune reactions, the cartilage in the secondary site is weaker. Autologous chondrocyte transplantation (ACI) is a method in which normal living cartilage tissue is removed from a secondary site in the knee joint, chondrocytes are cultured in a laboratory, proliferated to a sufficient amount, and implanted into a cartilage defect site, and the new state of chondrocytes is similar to that of natural articular cartilage. If the joint pathology is severe, the clinician may perform a rescue type of surgery, such as an osteotomy or total joint replacement.
The slow release of the medicine is to combine the micromolecule medicine with the macromolecule carrier by a physical or chemical method, and the micromolecule medicine is continuously released in proper concentration in vivo through control modes such as diffusion, permeation and the like, which is beneficial to improving the bioavailability of the medicine, reducing toxic and side effects, relieving the pain of patients after taking the medicine for many times, and further improving the clinical medication level. At present, the main developed drug sustained-release polymer carrier materials mainly include natural polymer materials, synthetic polymer materials and inorganic materials.
At present, chitosan is often used as a carrier of polypeptide, protein and antitumor drugs, drug release is regulated through self degradation, the drugs can be released at a relatively stable rate within several weeks or months, effective blood concentration is maintained, administration times of the half-life period of the drugs are reduced, and the chitosan is suitable for the drugs with short half-life period and long-term use.
With the development of tissue engineering technology, the damage repair of articular cartilage enters a new height, and the technology mainly comprises three elements of seed cells, a bracket material and cell growth factors, wherein the bracket material is used for simulating extracellular matrix, providing a proper microenvironment for the growth, proliferation and differentiation of cells at the defect part, and promoting the repair and regeneration of the articular cartilage by utilizing a natural biological process of interaction between the cells and biomolecules. Therefore, the success of tissue engineering depends to a large extent on the extent to which the scaffold mimics the extracellular matrix (ECM) of the corresponding tissue in structure and composition.
Injectable hydrogels have received a great deal of attention as candidate materials for cartilage repair. The aim is to directly inject hydrogel precursor liquid loaded with cells or growth factors into the defect part of the articular cartilage for in-situ filling, and then rapidly polymerize the hydrogel precursor liquid in a short time to form solid gel. The advantage of this strategy is that irregular shaped defects can be easily filled by minimally invasive surgery, not only can fusion well with the defect site, but also cells and bioactive factors can be uniformly incorporated in the hydrogel, and the injectable nano-compound solution of nanoparticles is used for cartilage repair as schematically shown in fig. 1.
In order to further improve the mechanical strength and stability of injectable hydrogels, some researchers have added fillers such as microsphere particles (e.g., gelatin, sodium alginate, chitosan microspheres), nanoparticles (e.g., hydroxyapatite, metal particles, clay), and nanofibers (e.g., albumin, electrospun PCL, silica nanofibers [45]) as injectable hydrogel materials for articular cartilage repair. The composite hydrogel has the excellent characteristics of pore communication, high compression modulus, good formability, reasonable degradability and the like, and is a matrix suitable for cartilage tissue engineering.
Autologous cartilage transplantation has advantages and disadvantages, has no immunological rejection, has disadvantages of low differentiation and low biological activity, and can be used for treating cartilage injury of small and medium size, and complication such as infection and postoperative pain due to invasive operation of cartilage cells. The source of allogeneic periosteum transplantation is sufficient, but immunological rejection reaction is easy to occur. Both approaches have limited clinical use. The application of gene therapy technology in cartilage injury still stays at the theoretical level at present, and the extraction, transfection and clinical mature application of genes are still explored.
Advanced skin ecology awakens the field of cell regeneration medicine and aesthetics of 'water stripping', which is the top technology from Europe and America, and professional anti-aging and wrinkle-removing technology activates a self-healing system of a human body to enable the operated part to 'grow reversely' within 28 days. The number of cells regenerated in this period is greater than the number of cells lost, and the subcutaneous reticular fibers are corrected and reconstructed. The "stripping" is to separate the distance between cells by means of the water expansion force, and after entering into the subcutaneous part, the water will avoid the capillary and nerve net, so as to complete the cell stripping without forming wound surface.
Bone Morphogenetic Proteins (BMPs) were first discovered and named by Urist. BMPs are a group of highly conserved functional proteins with similar structures, belonging to the transforming growth factor-P (TGF-P) superfamily. Recent studies have found that BMPs have various biological functions. The most interesting function of their developers is their ability to induce bone and cartilage formation in vivo.
BMP-2 is one of the most widely studied BMPs with the highest osteogenesis inducing activity. At present, a chemical synthesis method is used in China to synthesize a novel short peptide P17-BMP-2 containing 17 amino acids. The short peptide overcomes the defects of rhBMP-2 prepared by gene engineering technology at home and abroad. It is similar to BMP2 in bone induction activity, and has simple preparation process. Solves the problems that the rhBMP-2 can not be produced in a large scale and the safety is difficult. The P17-BMP-2 only contains 17 amino acids, can effectively overcome antigenicity brought by macromolecules and other biological side effects, and has an amino acid sequence of IVAPPGYHAFYCHGECP. The short peptide has simple structure, more stable biological property and better activity. Moreover, modification of the peptide chain is very convenient. It can be said that the nucleotide sequence inherits the activity of BMP-2, overcoming its disadvantages.
The guanidyl contained in the arginine-rich cell-penetrating peptide can be combined with phosphate and sulfate which are negatively charged on the surface of a cell membrane, so that the arginine-rich cell-penetrating peptide can efficiently penetrate through the cell membrane. Meanwhile, the cell-penetrating peptide has low cytotoxicity, so that the cell-penetrating peptide has application in the cell-penetrating field (Suncheng and the like, research progress of the cell-penetrating peptide. the poly-arginine (rR)3R2 hybridized by non-natural D-type arginine (R) and natural L-type arginine (R) can efficiently enter cells with low toxicity, and simultaneously has certain enzymolysis resistance and serum degradation resistance, so that the poly-arginine is concerned.
Bone defects caused by trauma, tumors, infection and the like are increasing year by year worldwide, and have greater and greater influence on the health of people. In our country, there are approximately 400 million patients that need to be treated because of bone defects each year. In addition to bone grafts required for disease-induced bone defects, bone grafts are often required for plastic shaping in cosmetic and plastic surgery. Bone graft materials have become the largest graft in demand next to blood transfusion, and have tended to increase year by year.
Disclosure of Invention
Aiming at the problems of the prior art that the cartilage repair transplantation material is in short supply and the effect is not ideal enough, the invention provides the biological combination preparation for cartilage repair, the biological combination preparation can be suitable for cartilage repair by the tissue engineering technology, the repair effect on cartilage injury is good, and the treatment is time-saving and quick.
In order to solve the technical problems, the invention adopts the following technical scheme:
the sequence of the known novel short peptide P17-BMP-2 is optimized by modification so as to increase the penetrability of the peptide.
Preferably, amino acid modifications are introduced into the sequence of P17-BMP-2 that are known to aid in membrane penetration.
Preferably, the polypeptide is modified with an amino acid having a membrane-penetrating property such as arginine, leucine or tryptophan.
Preferably, the sequence of the modified P17-BMP-2 short peptide molecule is XXIVXPPXYHAFYCHGECP, wherein X can be one selected from arginine, leucine and tryptophan.
Preferably, the length of the modified P17-BMP-2 short peptide molecule is 19 amino acids, and the preferred sequence can be RRIVLPPWYHAFYCHGECP.
The invention discloses a nano compound liquid for cartilage repair, which comprises the following components in part by weight: PBS buffer solution, hyaluronic acid and a nano microsphere particle compound, wherein the nano microsphere particle comprises microsphere particles, a filling agent and bone morphogenetic protein analogues.
Preferably, the microsphere particles are selected from chitosan microspheres, and the filling agent is selected from bovine serum albumin.
Preferably, the bone morphogenetic protein analog is prepared by artificial synthesis, and has the sequence of RRIVLPPWYHAFYCHGECP.
The invention discloses a cosmetic product which comprises the compound liquid.
The invention discloses a preparation method of a nano compound liquid, which comprises the following steps:
(1) preparing microsphere particles: weighing chitosan, dissolving in 2% v/v acetic acid, dripping into n-octanol, stirring at 1500rpm for 30 min; centrifuging, and discarding the upper aqueous phase; adding isopropanol, centrifuging and discarding the supernatant; adding double distilled water, centrifuging, discarding supernatant, sterilizing with ethylene oxide, and storing for use;
(2) dissolving BSA in hydrochloric acid aqueous solution, filtering for sterilization, and adding bone morphogenetic protein analogues to obtain bone morphogenetic protein analogue preserving fluid;
(3) weighing the microsphere particles obtained in the step (1), adding the preservation solution prepared in the step (2), placing in a shaking table, and fully and uniformly oscillating;
(4) centrifuging, washing by double distilled water, and centrifuging to obtain the nano microsphere particle compound.
Preferably, the bone morphogenetic protein analog is prepared by artificial synthesis, and has the sequence of RRIVLPPWYHAFYCHGECP.
Preferably, the method further comprises the following steps: (5) dissolving a hyaluronic acid stock solution in a PBS buffer solution;
(6) and (4) dissolving the nano microsphere particles prepared in the step (4) in the buffer solution prepared in the step (5).
The invention discloses a nano compound liquid for cartilage repair, which is prepared by adopting the method.
The invention discloses application of the nano compound liquid in preparing a beauty product.
Preferably, the cosmetic product is a cartilage damage cosmetic repair product.
Advantageous effects
The invention discloses a bone morphogenetic protein analogue, wherein the analogue polypeptide can induce the formation of osteocytes, the invention further utilizes the active peptide to prepare nano microsphere particles with a slow release function and corresponding nano compound liquid, the prepared compound liquid is utilized to realize the repair and regeneration of chondrocytes, and the analogue can be widely applied to the damage of joints and cartilages and the cosmetic repair, and has extremely high popularization value.
Drawings
Fig. 1 is a schematic view of an injectable nano-compound solution with nanoparticles added for cartilage repair;
FIG. 2 is the result of electron microscope examination of the prepared microspheroidal particles;
FIG. 3 is an immunohistochemical assay of type II collagen differentiation of BMSC cells into chondrocytes;
FIG. 4 is a result of observation of cultured MSC cells by an optical microscope, wherein A is an observation result after 1 day of culture and B is a result after 7 days of culture;
FIG. 5 is the result of AKP detection in MSC cells, wherein the abscissa is the number of days of cell culture and the ordinate is the AKP content in μ g/mL;
fig. 6 is the result of alizarin red staining about 2 weeks after MSC cell induction.
Detailed Description
The following detailed description of embodiments of the invention refers to the accompanying drawings. It should be understood that the detailed description and specific examples, while indicating the present invention, are given by way of illustration and explanation only, not limitation.
Example 1 preparation of microspheroidal particles and identification of microsphere morphology
1) Weighing 200mg of chitosan, and dissolving in 8ml of 2% v/v acetic acid solution;
2) gradually dripping the solution into 150ml of n-octanol, and stirring for 30 min;
3) adding 10ml of 8% w/vTPP solution, stirring for 30min at 1200 rpm;
4) centrifuging at 4000rpm, and discarding the upper aqueous phase;
5) adding 8ml of isopropanol, centrifuging at 2500 rpm, and removing supernatant;
6) adding 8ml of double distilled water, centrifuging at 2500 rpm, and removing supernatant;
7) repeating the steps 5 and 6 for 2-3 times;
8) sterilizing with ethylene oxide to obtain chitosan microsphere particles, and storing;
9) and scanning and observing the distribution and the form of the prepared microspheres by adopting an SEM electron microscope.
The electron microscope observation result shows that the prepared microspheres have uniform particle size, similar form and uniform dispersion, are good slow-control carriers, and the electron microscope inspection result is shown in figure 2.
Example 2 preparation of Nanoparticulate particle composite
(1) The synthetic bone morphogenetic protein analog was dissolved in PBS and had the sequence RRIVLPPWYHAFYCHGECP.
(2) Dissolving BSA in hydrochloric acid aqueous solution, filtering for sterilization, and adding bone morphogenetic protein analogues to obtain bone morphogenetic protein analogue preserving fluid;
(3) weighing the microsphere particles prepared in the example 1, adding the preservation solution prepared in the step (2), placing in a shaking table, and fully and uniformly oscillating;
(4) centrifuging, washing by double distilled water, and centrifuging to obtain the nano microsphere particle compound.
Example 3 Induction of chondrocyte differentiation in vitro by Nanoparticulate composites
Taking BMSC cells and mixing with 6X103The density of each hole is inoculated on a 16-hole cell culture plate, and when the cells are fused to about 70%, the nano microsphere particle compound prepared in the example 2 is added into the culture medium, and the concentration is about 0.5-2 mg/L. Culturing is continued for 15-20 days, and after 15 days of culturing, a part of the cells are taken out every day to perform a detection test of type II collagen immunohistochemistry, so as to identify the condition of BMSC cell differentiation into chondrocytes. Wherein, after about 18 days of culture, positive cells can be identified by an immunohistochemical test, which shows that some BMSC cells have differentiated into chondrocytes after being induced by the nanoparticle complex in vitro, wherein the detection result of type II collagen immunohistochemistry is shown in figure 3.
EXAMPLE 4 preparation of a Nanocomposition solution
(1) Dissolving sodium hyaluronate in water at room temperature to form a transparent solution with the mass fraction of 0.1%, adding cation exchange resin, stirring overnight, and filtering to obtain a hyaluronic acid stock solution;
(2) dissolving hyaluronic acid stock solution in PBS solution, and respectively storing according to the volume ratio of 2: 1;
(3) dissolving the nano microsphere particles prepared in the example 2 in the solution, and uniformly mixing according to the mass-volume ratio of 1:5 (g/mL);
(4) storing in two syringes connected in parallel, and aseptic packaging.
Example 5 Induction of differentiation of in vitro osteocytes by Nanocompositions
(1) Taking out the culture plate for culturing the mouse MSC cells from the incubator, discarding the culture solution, washing with PBS for 3 times, adding 1ml of trypsin digestion solution finished product into each hole, and digesting the cells;
(2) observing by an optical microscope, and immediately and completely stopping digestion when the cell gap is increased and the cells become round;
(3) transferring the cells into the centrifuge tube, adding the culture medium again, beating by blowing, repeating for multiple times until the cells float under the lens, and transferring the washing liquid into the centrifuge tube;
(4) centrifuging, removing supernatant, adding culture solution, blowing, mixing, and culturing in a 37 deg.C carbon dioxide incubator;
(5) the nano-composite solution prepared in example 4 was added to a concentration of about 1-2.5 mg/L. Continuing culturing, performing osteogenesis induction when cell fusion reaches more than 75%, and performing induction liquid change every three days;
(6) measuring alkaline phosphatase (according to the operation instruction of the alkaline phosphatase measuring kit) on the induced cells, wherein 1mL of cultured cells at different induction culture time points are taken, and are subjected to microscopic dilution to the same cell concentration, and then are measured by using the kit;
(7) cells approximately 2 weeks after osteogenic induction were stained with alizarin red and observed under an optical microscope.
The results of the observation of the cultured MSC cells by the optical microscope are shown in fig. 4, in which a is the observation after 1 day of culture in which the cells are already spindle-shaped, and B is the observation after 7 days of culture in which the growth of the cells is accelerated, fusion occurs, and most of the cells are spindle-shaped.
The results of the AKP detection in the cells are shown in FIG. 5, and the AKP content in the induced cells gradually increases with time.
Alizarin red staining results for cells at about 2 weeks after induction are shown in fig. 6, which indicates that calcium nodules have formed in the induced MSC cells.
The induced differentiation of osteocytes can be successfully realized by adopting the nano compound liquid and the nano microsphere particle compound provided by the application. Therefore, the method can be widely applied to joint and cartilage damage and cosmetic repair, and has high popularization and application values.
The present invention is illustrated by the above examples, but the present invention is not limited to the above process steps, which means that the present invention must not be dependent on the above process steps. It will be apparent to those skilled in the art that any modifications to the present invention, equivalent substitutions of selected materials and additions of auxiliary components, selection of specific forms, etc., are within the scope and disclosure of the present invention.
Claims (8)
1. A nano-composite fluid for cartilage repair, the composite fluid comprising: the bone morphogenetic protein comprises PBS buffer solution, hyaluronic acid and a nano microsphere particle compound, wherein the nano microsphere particle compound comprises microsphere particles, a filling agent and a bone morphogenetic protein analogue, the bone morphogenetic protein analogue is prepared in an artificial synthesis mode, and the sequence of the bone morphogenetic protein analogue is RRIVLPPWYHAFYCHGECP.
2. The compound fluid of claim 1, wherein the microsphere particles are selected from chitosan microspheres and the bulking agent is selected from bovine serum albumin.
3. A cosmetic preparation comprising the complex liquid according to any one of claims 1-2.
4. The method for preparing the nano-compound liquid as claimed in claim 1, which is characterized by comprising the following steps:
(1) preparing microsphere particles: weighing chitosan, dissolving in 2% v/v acetic acid, dripping into n-octanol, stirring at 1500rpm for 30 min; centrifuging, and discarding the upper aqueous phase; adding isopropanol, centrifuging and discarding the supernatant; adding double distilled water for centrifugation, abandoning the supernatant, and storing for later use, wherein the epoxy brick is manufactured by a sintered method and is sterilized;
(2) dissolving BSA in hydrochloric acid aqueous solution, filtering for sterilization, and adding bone morphogenetic protein analogues to obtain bone morphogenetic protein analogue preserving fluid;
(3) weighing the microsphere particles obtained in the step (1), adding the preservation solution prepared in the step (2), placing in a shaking table, and fully and uniformly oscillating;
(4) centrifuging, washing by double distilled water, and centrifuging to obtain a nano microsphere particle compound; the bone morphogenetic protein analogue is prepared by adopting an artificial synthesis mode, and the sequence of the bone morphogenetic protein analogue is RRIVLPPWYHAFYCHGECP.
5. The method of claim 4, further comprising: (5) dissolving a hyaluronic acid stock solution in a PBS buffer solution;
(6) and (4) dissolving the nano microsphere particle compound prepared in the step (4) in the buffer solution prepared in the step (5).
6. A nano-compound liquid for cartilage repair, which is prepared by the method of claims 4-5.
7. Use of the nano-composite liquid according to claim 6 for preparing a cosmetic product.
8. Use according to claim 7, characterized in that the cosmetic product is a cartilage damage cosmetic repair product.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110775346.9A CN113559324B (en) | 2021-07-08 | 2021-07-08 | Application of nano compound liquid in chondrocyte self-repair and regenerative medicine aesthetics |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110775346.9A CN113559324B (en) | 2021-07-08 | 2021-07-08 | Application of nano compound liquid in chondrocyte self-repair and regenerative medicine aesthetics |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113559324A CN113559324A (en) | 2021-10-29 |
CN113559324B true CN113559324B (en) | 2022-06-24 |
Family
ID=78164179
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110775346.9A Active CN113559324B (en) | 2021-07-08 | 2021-07-08 | Application of nano compound liquid in chondrocyte self-repair and regenerative medicine aesthetics |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113559324B (en) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101502675A (en) * | 2008-02-04 | 2009-08-12 | 山东省药学科学院 | Suspension of hyaluronic acid or salt thereof containing macromolecule hydrogel for injection and preparation method thereof |
CN101759812A (en) * | 2009-12-28 | 2010-06-30 | 中国药科大学 | Novel chitosan derivative simulating the structure of cell-penetrating peptide |
CN102031269A (en) * | 2010-11-23 | 2011-04-27 | 湖南师范大学 | Method for preparing cationic amino acid-containing polypeptide-modified nano calcium phosphate gene vector |
CN102139096A (en) * | 2011-03-22 | 2011-08-03 | 华东理工大学 | Injectable biological active factor composition and preparation method and application thereof |
CN104436298A (en) * | 2013-09-17 | 2015-03-25 | 中国人民解放军第二军医大学 | Injectable PLGA porous composite microsphere preparation embedded with BMP-2 containing particles and preparation method and application thereof |
CN112754996A (en) * | 2021-03-16 | 2021-05-07 | 江西省科学院生物资源研究所 | Protamine short peptide modified paclitaxel liposome and preparation method thereof |
-
2021
- 2021-07-08 CN CN202110775346.9A patent/CN113559324B/en active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101502675A (en) * | 2008-02-04 | 2009-08-12 | 山东省药学科学院 | Suspension of hyaluronic acid or salt thereof containing macromolecule hydrogel for injection and preparation method thereof |
CN101759812A (en) * | 2009-12-28 | 2010-06-30 | 中国药科大学 | Novel chitosan derivative simulating the structure of cell-penetrating peptide |
CN102031269A (en) * | 2010-11-23 | 2011-04-27 | 湖南师范大学 | Method for preparing cationic amino acid-containing polypeptide-modified nano calcium phosphate gene vector |
CN102139096A (en) * | 2011-03-22 | 2011-08-03 | 华东理工大学 | Injectable biological active factor composition and preparation method and application thereof |
CN104436298A (en) * | 2013-09-17 | 2015-03-25 | 中国人民解放军第二军医大学 | Injectable PLGA porous composite microsphere preparation embedded with BMP-2 containing particles and preparation method and application thereof |
CN112754996A (en) * | 2021-03-16 | 2021-05-07 | 江西省科学院生物资源研究所 | Protamine short peptide modified paclitaxel liposome and preparation method thereof |
Also Published As
Publication number | Publication date |
---|---|
CN113559324A (en) | 2021-10-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Ye et al. | Three-dimensional electrospun nanofibrous scaffolds displaying bone morphogenetic protein-2-derived peptides for the promotion of osteogenic differentiation of stem cells and bone regeneration | |
Venkatesan et al. | Alginate composites for bone tissue engineering: A review | |
CN107213523B (en) | A kind of preparation method of co-crosslinked double network hydrogel scaffold for promoting osteogenic growth | |
US8137696B2 (en) | Biomimetic composition reinforced by a polyelectrolytic complex of hyaluronic acid and chitosan | |
EP4023240A1 (en) | Purified amphiphilic peptide compositions and uses thereof | |
Zhang et al. | Injectable composite hydrogel promotes osteogenesis and angiogenesis in spinal fusion by optimizing the bone marrow mesenchymal stem cell microenvironment and exosomes secretion | |
US9889233B2 (en) | Method of producing native components, such as growth factors or extracellular matrix proteins, through cell culturing of tissue samples for tissue repair | |
CN112972760B (en) | Endothelial extracellular matrix loaded 3D printing bone defect repair support and preparation method thereof | |
CN110665055B (en) | Sericin/nano-hydroxyapatite tissue engineering bone graft and preparation method and application thereof | |
WO2023179544A1 (en) | 3d-printed bone defect repair scaffold loaded with mesenchymal stem cell extracellular matrixes and preparation method therefor | |
Li et al. | Synthesis and evaluation of BMMSC-seeded BMP-6/nHAG/GMS scaffolds for bone regeneration | |
CN117338816B (en) | Stem cell preparation for treating arthritis and preparation method thereof | |
RU2483756C1 (en) | METHOD FOR PREPARING BIODEGRADED COMPOSITE MATRIX OF REGENERATED SILK FIBROIN Bombyx mori AND ITS USE | |
CN112521638A (en) | Hydrogel loaded with bone morphogenetic protein, preparation method and application | |
CN115501393B (en) | Hydrogel for repairing nerve defects and preparation method and application thereof | |
CN115702952A (en) | Injectable bone constructed based on injectable hydrogel scaffold material and application thereof | |
Zhu et al. | Nano-Hydroxyapatite scaffold based on recombinant human bone morphogenetic protein 2 and its application in bone defect repair | |
CN113559324B (en) | Application of nano compound liquid in chondrocyte self-repair and regenerative medicine aesthetics | |
CN111686308A (en) | Charged gelatin nanosphere colloidal gel and preparation method and application thereof | |
Guo et al. | Engineering niches for cartilage tissue regeneration | |
WO2021081484A1 (en) | Rotator cuff therapy using muscle fiber fragments | |
Wuran et al. | Application of silk fibroin composite scaffold in bone tissue engineering | |
Papagiannopoulos et al. | Biological macromolecules for growth factor delivery in bone regeneration | |
CN119303164A (en) | A biomimetic frog-derived nerve regeneration peptide-modified bioactive hydrogel and preparation method thereof | |
CN112717204A (en) | Autologous bone graft activity substitute composition, preparation method and application |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |